The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV
Lisa O’Brien, Nathan Shaffer, Nalinee Sangrujee & Taiwo O Abimbola
Volume 92, Number 3, March 2014, 162-170
Table 2. Time spent per woman in Option Ba or Option B+b over 5 years postpartum
|Breastfeeding status and duration||CD4+ count 350–500 cells/µl
||CD4+ count > 500 cells/µl
|Months spent in care (pre-ART)||First 12 months on ART||Remaining months on ART||Months spent in care (pre-ART)||First 12 months on ART||Remaining months on ART|
ART, antiretroviral therapy.
a Option B comprises a maternal triple antiretroviral (ARV) regimen, typically consisting of the recommended first-line ART, during pregnancy and throughout breastfeeding, in combination with 6 weeks of daily nevirapine for the infant, regardless of infant feeding method.
b Option B+ comprises a triple ARV regimen initiated during pregnancy and continued for life.
c Includes duration of breastfeeding.